Literature DB >> 32457372

Dendritic cells with METTL3 gene knockdown exhibit immature properties and prolong allograft survival.

Hongbing Wu1, Zhaojia Xu2, Zhiwei Wang3, Zongli Ren1, Luocheng Li1, Yongle Ruan1.   

Abstract

Maturation of dendritic cells (DCs) initiates adaptive immune responses and thereby provokes allograft rejection. Here, this study aimed to explore the effect of Methyltransferase-like protein 3 (METTL3) silencing on DC function and the role of METTL3-silencing donor DCs in the immune response after mouse heart transplantation. Bone marrow-derived DCs from donor BALB/c mice were infected with lentiviruses expressing METTL3-specific short hairpin RNA (LV-METTL3 shRNA) to silence METTL3. Then METTL3-silencing DCs were treated with lipopolysaccharide (LPS) for another 48 h to induce DC maturation. Recipient C57BL/6 mice were injected with phosphate-buffered saline (PBS), immature DCs, and METTL3 shRNA-DCs prior to the cardiac transplantation involving the transfer of hearts from donor BALB/c mice to recipient C57BL/6 mice. In vitro we demonstrated that METTL3-silencing DCs had lower expression of MHCII, costimulatory molecules (CD80, CD86), and DC-related cytokines (IFN-γ, IL-12) as well as lower ability to activate T-cell proliferation, which were consistent with the characteristics of tolerogenic DCs. In vivo we found that METTL3-silencing donor DCs induced immune tolerance after mouse heart transplantation and prolonged the allograft survival, which might be associated with Th1/Th2 immune deviation. In summary, METTL3-silencing DCs exhibit immature properties and prolong allograft survival.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32457372     DOI: 10.1038/s41435-020-0099-3

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  4 in total

Review 1.  Regulatory Dendritic Cells, T Cell Tolerance, and Dendritic Cell Therapy for Immunologic Disease.

Authors:  Sara Ness; Shiming Lin; John R Gordon
Journal:  Front Immunol       Date:  2021-03-10       Impact factor: 7.561

Review 2.  Targeting the RNA m6A modification for cancer immunotherapy.

Authors:  Xinxin Li; Shoubao Ma; Youcai Deng; Ping Yi; Jianhua Yu
Journal:  Mol Cancer       Date:  2022-03-16       Impact factor: 27.401

3.  Nanodrug enhances post-ablation immunotherapy of hepatocellular carcinoma via promoting dendritic cell maturation and antigen presentation.

Authors:  Zecong Xiao; Tan Li; Xinyao Zheng; Liteng Lin; Xiaobin Wang; Bo Li; Jingjun Huang; Yong Wang; Xintao Shuai; Kangshun Zhu
Journal:  Bioact Mater       Date:  2022-08-14

Review 4.  The Emerging Clinical Application of m6A RNA Modification in Inflammatory Bowel Disease and Its Associated Colorectal Cancer.

Authors:  Xinwei Xu; Jintu Huang; Dickson Kofi Wiredu Ocansey; Yuxuan Xia; Zihan Zhao; Zhiwei Xu; Yongmin Yan; Xu Zhang; Fei Mao
Journal:  J Inflamm Res       Date:  2021-07-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.